Episode
#197 Hypercoagulability Part 2: 5 Pearls Segment
- Published
- Jan 7, 2026
- Duration seconds
- 2306
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/core-im-internal-medicine-podcast-60389/episodes/197-hypercoagulability-part-2-5-pearls-segment/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389/197-hypercoagulability-part-2-5-pearls-segment.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Gray zones of VTE management! How to approach anticoagulation duration in unprovoked, provoked-irreversible, and provoked-reversible clots? When dose-reduced DOACs make sense for long-term secondary prevention? What truly constitutes DOAC failure? We also devle into how APLAS a critical do-not-miss diagnosis that changes management entirely. 🔹 Sponsor : Pain Management and Opioids Adaptive Learning Free Online Course by NEJM Group: https://cme-info.nejm.org/core-im/ 🔹 Transcript & Shownotes (2:56) - (13:15) | PEARL 1: Managing clots in the “unprovoked”/provoked-irreversible patient (13:21) - (18:10) | PEARL 2: Managing provoked, “reversible” clots (18:14) - (25:14) | PEARL 3: DOAC failure: time to step it up? (25:20) - (37:25) | PEARL 4: APLAS: the exception to everything Tags: CoreIM, Internal Medicine, ClinicalPearls, Medical Education, IMCore, hospitalist, physician assistant, nurse practitioner, medical student, internal medicine, hematology Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy